BRPI0001486B8 - processos e intermediários para preparar compostos anticancerígenos - Google Patents

processos e intermediários para preparar compostos anticancerígenos

Info

Publication number
BRPI0001486B8
BRPI0001486B8 BRPI0001486A BR0001486A BRPI0001486B8 BR PI0001486 B8 BRPI0001486 B8 BR PI0001486B8 BR PI0001486 A BRPI0001486 A BR PI0001486A BR 0001486 A BR0001486 A BR 0001486A BR PI0001486 B8 BRPI0001486 B8 BR PI0001486B8
Authority
BR
Brazil
Prior art keywords
intermediates
processes
compounds
anticancer compounds
preparing
Prior art date
Application number
BRPI0001486A
Other languages
English (en)
Other versions
BR0001486A (pt
BRPI0001486B1 (pt
Inventor
Paul Santafianos Dinos
Shelton Lehner Richard
Norris Timothy
Original Assignee
Osi Pharm Inc
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc, Pfizer Prod Inc filed Critical Osi Pharm Inc
Publication of BR0001486A publication Critical patent/BR0001486A/pt
Publication of BRPI0001486B1 publication Critical patent/BRPI0001486B1/pt
Publication of BRPI0001486B8 publication Critical patent/BRPI0001486B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

patente de invenção: <b>"processos e intermediários para preparar compostos anticancerígenos"<d>. a presente invenção refere-se a métodos e intermediários para preparação de compostos de fórmula <mu>1<mv> e os sais farmaceuticamente aceitáveis e solvatos resultantes, bem como a compostos estruturalmente relacionados, em que r¹, r² e r^ 15^ são como aqui definidos. os compostos precedentes são úteis no tratamento de distúrbios hiperproliferativas, tais como cânceres, em mamíferos.
BRPI0001486A 1999-03-31 2000-03-27 processos e intermediários para preparar compostos anticancerígenos BRPI0001486B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (3)

Publication Number Publication Date
BR0001486A BR0001486A (pt) 2001-05-02
BRPI0001486B1 BRPI0001486B1 (pt) 2019-01-29
BRPI0001486B8 true BRPI0001486B8 (pt) 2021-05-25

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0001486A BRPI0001486B8 (pt) 1999-03-31 2000-03-27 processos e intermediários para preparar compostos anticancerígenos

Country Status (50)

Country Link
US (1) US6476040B1 (pt)
EP (1) EP1044969B1 (pt)
JP (2) JP3420549B2 (pt)
KR (2) KR100430210B1 (pt)
CN (2) CN100351242C (pt)
AP (2) AP1655A (pt)
AR (1) AR018705A1 (pt)
AT (1) ATE348098T1 (pt)
AU (2) AU781402B2 (pt)
BG (1) BG65194B1 (pt)
BR (1) BRPI0001486B8 (pt)
CA (2) CA2302965C (pt)
CO (1) CO5160273A1 (pt)
CR (1) CR6165A (pt)
CZ (1) CZ299426B6 (pt)
DE (1) DE60032275T2 (pt)
DK (1) DK1044969T3 (pt)
DZ (1) DZ3030A1 (pt)
EA (3) EA004654B1 (pt)
EE (1) EE04589B1 (pt)
EG (1) EG22506A (pt)
ES (1) ES2278578T3 (pt)
GE (1) GEP20022653B (pt)
GT (1) GT200000037A (pt)
HK (1) HK1029790A1 (pt)
HR (1) HRP20000182B1 (pt)
HU (1) HU227698B1 (pt)
ID (1) ID25427A (pt)
IL (2) IL135245A0 (pt)
IS (1) IS2468B (pt)
MA (1) MA25087A1 (pt)
MY (1) MY136270A (pt)
NO (2) NO321952B1 (pt)
NZ (2) NZ503683A (pt)
OA (1) OA11335A (pt)
PA (1) PA8491901A1 (pt)
PE (1) PE20001599A1 (pt)
PL (1) PL339330A1 (pt)
PT (1) PT1044969E (pt)
RS (1) RS49836B (pt)
SG (2) SG121687A1 (pt)
SK (1) SK287339B6 (pt)
SV (1) SV2002000047A (pt)
TN (1) TNSN00064A1 (pt)
TR (1) TR200000837A2 (pt)
TW (1) TW553939B (pt)
UA (2) UA80955C2 (pt)
UY (1) UY26086A1 (pt)
YU (1) YU13200A (pt)
ZA (1) ZA200001586B (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
CA2538884C (en) 2003-09-16 2010-09-21 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
PT1746999E (pt) * 2004-05-06 2012-01-11 Warner Lambert Co 4-fenilamino-quinazolin-6-il-amidas
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
EP1859793B1 (en) 2005-02-28 2011-04-20 Eisai R&D Management Co., Ltd. Novel combinational use of a sulfonamide compound in the treatment of cancer
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006309551B2 (en) * 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
EP2036557B1 (en) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
WO2008012105A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
EP2170844B1 (en) * 2007-02-21 2016-05-04 Natco Pharma Limited Novel polymorphs of erlotinib hydrochloride and method of preparation
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
WO2009025876A2 (en) * 2007-08-23 2009-02-26 Plus Chemicals, S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2248804A4 (en) * 2008-01-29 2014-09-10 Eisai R&D Man Co Ltd COMBINED USE OF AN ANGIOGENESIS INHIBITOR AND A TAXANE
CN102083801A (zh) * 2008-03-28 2011-06-01 康瑟特制药公司 喹唑啉衍生物和治疗方法
WO2010005924A1 (en) * 2008-07-07 2010-01-14 Plus Chemicals Sa Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011058525A2 (en) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
PL196940B1 (pl) 1998-04-29 2008-02-29 Osi Pharmaceuticals Bezwodna postać i monohydrat mesylanu N-(3-etynylofenylo)-6,7-bis (2-metoksyetoksy)-4-chinazolinaminy

Also Published As

Publication number Publication date
EP1044969B1 (en) 2006-12-13
IS2468B (is) 2008-12-15
PL339330A1 (en) 2000-10-09
CA2427221C (en) 2008-09-16
EA200000274A2 (ru) 2000-10-30
NO321952B1 (no) 2006-07-24
AU2005201494A1 (en) 2005-05-05
CR6165A (es) 2008-10-10
PA8491901A1 (es) 2001-12-14
AP1265A (en) 2004-03-26
HU227698B1 (en) 2011-12-28
ATE348098T1 (de) 2007-01-15
SK4442000A3 (en) 2000-10-09
GEP20022653B (en) 2002-03-25
AU2005201494B2 (en) 2008-02-07
CN1215061C (zh) 2005-08-17
CZ299426B6 (cs) 2008-07-23
DK1044969T3 (da) 2007-04-23
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
CN1276370A (zh) 2000-12-13
KR100430210B1 (ko) 2004-05-03
EA005892B1 (ru) 2005-06-30
CA2302965C (en) 2004-02-17
YU13200A (sh) 2002-10-18
PT1044969E (pt) 2007-05-31
HUP0001353A3 (en) 2002-01-28
UA80955C2 (en) 2007-11-26
NO20001648D0 (no) 2000-03-30
OA11335A (en) 2003-12-10
IS5411A (is) 2000-10-02
KR20010014658A (ko) 2001-02-26
BG104278A (en) 2001-08-31
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
EP1044969A3 (en) 2000-11-29
EA200201245A1 (ru) 2003-04-24
BR0001486A (pt) 2001-05-02
SG115536A1 (en) 2005-10-28
CA2427221A1 (en) 2000-09-30
JP3420549B2 (ja) 2003-06-23
ES2278578T3 (es) 2007-08-16
EE200000255A (et) 2000-12-15
PE20001599A1 (es) 2001-01-18
HRP20000182A2 (en) 2001-04-30
SG121687A1 (en) 2006-05-26
CA2302965A1 (en) 2000-09-30
MY136270A (en) 2008-09-30
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
EE04589B1 (et) 2006-02-15
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
JP2000290262A (ja) 2000-10-17
ZA200001586B (en) 2001-10-01
DE60032275T2 (de) 2007-07-12
CN1699350A (zh) 2005-11-23
SK287339B6 (sk) 2010-07-07
NO20054715L (no) 2000-10-02
CZ20001155A3 (cs) 2001-03-14
EA005561B1 (ru) 2005-04-28
CO5160273A1 (es) 2002-05-30
BRPI0001486B1 (pt) 2019-01-29
IL135245A0 (en) 2001-05-20
HUP0001353A2 (hu) 2001-05-28
HK1029790A1 (en) 2001-04-12
NO20001648L (no) 2000-10-02
MA25087A1 (fr) 2000-10-01
TW553939B (en) 2003-09-21
KR100430209B1 (ko) 2004-05-03
TR200000837A2 (tr) 2000-11-21
EA200201244A1 (ru) 2003-04-24
KR20020084903A (ko) 2002-11-13
DE60032275D1 (de) 2007-01-25
NZ512818A (en) 2003-01-31
BG65194B1 (bg) 2007-06-29
CN100351242C (zh) 2007-11-28
HU0001353D0 (en) 2000-06-28
EA200000274A3 (ru) 2003-02-27
JP2003176274A (ja) 2003-06-24
UY26086A1 (es) 2000-10-31
US6476040B1 (en) 2002-11-05
SV2002000047A (es) 2002-01-23
GT200000037A (es) 2001-09-21
JP4074509B2 (ja) 2008-04-09
DZ3030A1 (fr) 2004-03-27
UA70928C2 (uk) 2004-11-15
AR018705A1 (es) 2001-11-28
AP1655A (en) 2006-09-01
NZ503683A (en) 2001-09-28
RS49836B (sr) 2008-08-07
ID25427A (id) 2000-10-05
AU781402B2 (en) 2005-05-19
EA004654B1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
BRPI0001486B8 (pt) processos e intermediários para preparar compostos anticancerígenos
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR0313942A (pt) Derivados de benzimidazol úteis como agentes antiproliferativos
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR9810021A (pt) Derivados 9-oxima-eritromicina
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR9913138A (pt) Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4&#34;-substituìdos&#34;
NO20020725L (no) Celleadhesjonsinhibitorer
TR200201638T2 (tr) Yeni imidazo[1,3,5]triazinonlar ve kullanımları
DK1056704T3 (da) Antitumormidler
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ATE178056T1 (de) Substituierte tertiäre amine und deren salze
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
ATE282605T1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
UA66866C2 (uk) Синтез морфолінових похідних
BR9910206A (pt) Derivados de higromicina a.
BR0214578A (pt) Compostos azopolicìclicos fundidos com arila
DE60000978T2 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
TR200200017T2 (tr) Benzofuran türevleri
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFIZER PRODUCTS INC. (US) , OSI PHARMACEUTICALS, I

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: PFIZER PRODUCTS INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2256 NA DATA 01/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27/03/2020